# Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients

> **NCT00386373** · NA · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Imatinib Mesylate

## Key facts

- **NCT ID:** NCT00386373
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2012-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00386373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00386373, "Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00386373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*